SCHEDULE: Suvretta Capital Maintains 7.7% Stake in Sutro Biopharma
Schedule 13G Amendment
Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an amended Schedule 13G, confirming a 7.7% beneficial ownership stake in Sutro Biopharma, Inc.
Summary
- Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen collectively reported beneficial ownership of 6,488,324 shares of Sutro Biopharma, Inc. Common Stock.
- This represents 7.7% of the class of securities.
- The filing is an Amendment No. 4 to a Schedule 13G, indicating a passive investment purpose.
- The shares are held with shared voting and shared dispositive power by the reporting persons.
- Averill Master Fund, Ltd. directly owns 6,461,305 shares, also representing 7.7% of the class.
- All reported securities are directly owned by advisory clients of Suvretta Capital Management, LLC, with Averill Master Fund, Ltd. being the only advisory client deemed to beneficially own more than 5%.
- Aaron Cowen is identified as the control person for Suvretta Capital Management, LLC.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of beneficial ownership, indicating no change in the passive investment intent.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of passive institutional ownership in a biopharmaceutical company, common among investment funds that hold significant, non-controlling stakes in publicly traded entities.
Related Party Transactions
- All securities reported are directly owned by advisory clients of Suvretta Capital Management, LLC.
- Averill Master Fund, Ltd. is an advisory client of Suvretta Capital Management, LLC and is deemed to beneficially own more than 5% of the Common Stock.
- Aaron Cowen is identified as the control person for Suvretta Capital Management, LLC.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant passive institutional ownership, confirming the continued stake of Suvretta Capital Management and its affiliates.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement |
| 08/13/2025 | Date of Joint Filing Agreement and filing date of Schedule 13G Amendment No. 4 |
Keywords
Sutro Biopharma, Suvretta Capital Management, Averill Master Fund, Aaron Cowen, Schedule 13G, Beneficial Ownership, Common Stock, Biopharma Investment, Institutional Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.